Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen

Breast Cancer

Volumn 5, Issue 2, 1998, Pages 99-106

  Levenson, Anait S ^a   Wolf, Douglas M ^a   Catherino, William H ^a   Takei, Hiroyuki ^a   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug resistance; Estrogen receptor (ER); Raloxifene; Tamoxifen

Indexed keywords

EID: 0008286724     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966681     Document Type: Review

References (56)

1. Jordan VC: Current view of the use of tamoxifen for the treatment and prevention of breast cancer; Gaddum Memorial Lecture. Br J Pharmacol 110:507-517, 1993. (Pubitemid 23279253)
2. Jordan VC: Antitumour activity of the antioestrogen ICI46, 474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974.
3. Jordan VC: Effect of tamoxifen (ICI46.474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 12:419-424, 1976.
4. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 2:282, 1985. (Pubitemid 15047587)
5. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility to tamoxifen for prevention of breast cancer. Br J Cancer 60:126-133, 1989.
6. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984. (Pubitemid 14015738)
7. Jordan VC, Phelps E, Lindgren JU: Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35, 1987. (Pubitemid 18038542)
8. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
9. Gottardis MM, Robinson SP, Satyaswaroop PG, et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988. (Pubitemid 18061868)
10. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32 A: 1464-1476, 1996. (Pubitemid 26279109)
11. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer; Eighth Cain Memorial Lecture. Cancer Res 50:4177-4189, 1990. (Pubitemid 20225648)
12. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci 32:1031-1036, 1983. (Pubitemid 13193215)
13. Gottardis MM, Jordan VC: The antitumor action of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987. (Pubitemid 17108463)
14. Gottardis MM, Ricchio MD, Satyaswaroop PG, et al: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192, 1990. (Pubitemid 20190116)
15. Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:378-414, 1962.
16. Gorski J, Toft D, Shyamala G, et al: Hormone receptors; Studies on the interaction of estrogen with the uterus. Recent Prog Horm Res 24:45-80, 1968.
17. Jensen EV, Block GE, Smith S, et al: Estrogen receptors and breast cancer response to adrenalectomy. In: Hall TC ed, Prediction of Response in Cancer Therapy. Monogr Natl Cancer Inst 34:55-70, 1971.
18. Jordan VC: William L. MaGuire Memorial Lecture; "Studies on the estrogen receptor in breast cancer"; 20 years as a target for the treatment and prevention of breast cancer. Breast Cancer Res Treat 36:267-285, 1995
19. Brzozowski AM, Pike ACW, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758, 1997. (Pubitemid 27458965)
20. Danielian PS, White R, Lees JA, et al: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033, 1992.
21. Tzukerman MT, Esty A, Santiso-Mere D, et al: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 18:21-30, 1994. (Pubitemid 24034253)
22. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBOJ 9:2811-2818, 1990.
23. Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276, 1984. (Pubitemid 15189558)
24. Lednicer D, Lyster SC, Aspergren BD, et al: Mammalian antifertility agents, III; 1-Anyl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-anyl-2-phenyl-3,4-dihydronaphthalenes and their derivatives. J Med Chem 9:172-176, 1996.
25. Clark ER, Jordan VC: Oestrogenic, antiestrogenic and antifertility properties of a series of compounds related to ethamoxytriphetol (MER-25). Br J Pharmacol 57:487-493, 1976.
26. Robertson DW, Katzenellenbogen JA, Hayes JR, et al: Antiestrogen basicity-activity relationships; A comparison of the estrogen receptor binding and antituterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4- [2-(dimethylamino) ethoxy] phenyl]-1-butene (Tamoxifen, Nolvadex) having altered basicity. J Med Chem 25:167-171, 1982. (Pubitemid 12106638)
27. Jordan VC, Gosden B: Importance of the alkylaminoethoxy side chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 27:291-306, 1982. (Pubitemid 12052496)
28. Tate AC, Greene GL, De Sombre ER, et al: Differences between estrogen and antiestrogen-estrogen receptor complexes identified with an antibody raised against the estrogen receptor. Cancer Res 44:1012-1018, 1984. (Pubitemid 14152784)
29. Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4741-4745, 1983. (Pubitemid 13096361)
30. Morrow M, Jordan VC: Molecular mechanism of resistance to tamoxifen therapy in breast cancer. Arch Surg 128:1187-1191, 1993. (Pubitemid 23334821)
31. Howell A, Dodwell DJ, Anderson H: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617, 1992.
32. Canney PA, Griffiths T, Latief TN, et al: Clinical significance of tamoxifen withdrawal response. Lancet i: 36, 1987.
33. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens; Problems and potential for future clinical applications. Breast Cancer Res Treat 3(suppl):73-86, 1983. (Pubitemid 14127069)
34. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in athymic nude mice; Cytostatic effects of long-term antiestrogenic activity. Eur J Cancer Clin Oncol 23:1189-1196, 1987. (Pubitemid 17112483)
35. Gottardis MM, Robinson SP, Jordan VC: Estradiolstimulated growth of MCF-7 tumors implanted in athymic mice; A model to study the tumoristatic action of tamoxifen. J Steroid Biochem 20:311-314, 1988.
36. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988.
37. Gottardis MM, Wager RJ, Borden EC, et al: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765-4769, 1989. (Pubitemid 19213621)
38. Robinson SP, Langan-Fahey SM, Johnson DA, et al: Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43, 1991.
39. Wolf DM, Langan-Fahey SM, Parker CP, et al: Investigation of the mechanism of tamoxifenstimulated breast tumor growth using non-isomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 85:806-812, 1993. (Pubitemid 23150312)
40. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989. (Pubitemid 19207240)
41. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer. J Natl Cancer Inst 87:746-750, 1995.
42. Mahfoudi A, Poulet E, Dauvois S, et al: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206-4210, 1995
43. Bilimoria MM, Assikis VJ, Muenzner HD, et al: An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J Steroid Biochem Mol Biol 58:479-488, 1996. (Pubitemid 126657493)
44. Wolf DM, Jordan VC: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31:117-127, 1994. (Pubitemid 24264218)
45. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129-138, 1994. (Pubitemid 24264219)
46. Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84:580-591, 1992.
47. Jiang SY, Parker CJ, Jordan VC: A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 26:139-148, 1993.
48. Jiang SY, Langan-Fahey SM, Stella A, et al: Point mutation of the estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNA's for ER. Mol Endocrinol 6:2167-2174, 1992. (Pubitemid 23021567)
49. Tora L, Mullick A, Metzger D, et al: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8:1981-1986, 1989. (Pubitemid 19273524)
50. Catherino WH, Wolf DM, Jordan VC: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogue. Mol Endocrinol 9:1053-1063, 1995.
51. Catherino WH, Jordan VC: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92:39-47, 1995.
52. Jeng M-H, Jiang S-Y, Jordan VC: Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER Cancer Lett 82:123-128, 1994. (Pubitemid 24231975)
53. Jordan VC, Jiang SY, Catherino WH, et al: Regulation of cell growth with the transfected estrogen-receptor gene. In: Motta M, Serio M eds, Sex Hormones and Antihormones in Endocrine Dependent Pathology; Basic and Clinical Aspects, Elsevier Science B V, Amsterdam, pp243-248, 1994.
54. Levenson AS, Catherino WH, Jordan VC: Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60:261-268, 1997. (Pubitemid 27278057)
55. Levenson AS, Tonetti DA, Jordan VC: The estrogenlike effect of 4-hydroxytamoxifen on transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer, 1998. In press.
56. McDonnell DP, Clemm DL, Hermann T, et al: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669, 1995.